Chemico-genetic strategies to inhibit the leukemic potential of threonine aspartase-1Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemiaIdentification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingThe blind men and the AML elephant: can we feel the progress?Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsInterpretation of cytogenetic results in multiple myeloma for clinical practiceMutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomasTargeting the Pim kinases in multiple myelomaThe emerging role of Twist proteins in hematopoietic cells and hematological malignanciesAcute promyelocytic leukemia: where did we start, where are we now, and the futureInduced pluripotent stem cells in hematology: current and future applicationsDistribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaPrognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupMolecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.New investigational drugs with single-agent activity in multiple myelomaThe role of maintenance therapy in multiple myeloma'Acute myeloid leukemia: a comprehensive review and 2016 update'CircRNAs in hematopoiesis and hematological malignanciesEfficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasmsOutcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.MATE1 regulates cellular uptake and sensitivity to imatinib in CML patientsDrug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia.Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.The complexity of interpreting genomic data in patients with acute myeloid leukemia.Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndromeEfficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibSiltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialChronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatmentEZH2 alterations in follicular lymphoma: biological and clinical correlations.Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma.Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.
P1433
Q24294269-8FA149CA-B9ED-494D-94A7-6481506C3FD5Q24311970-F9D00C1F-0E6D-425C-BA2A-DADC35E97247Q24627782-AF764DC0-74E7-4F81-94C6-92972A47AEFCQ26749614-6EC2C2E2-7084-49AE-B6CF-B884DDD97090Q26768600-85BF31D1-86B8-456C-9F2E-0AA3B9CD5FC5Q26772881-A22FB2A7-6ED5-4147-ADE8-37F23690735CQ26777265-9816CA38-0AD6-494F-9CDC-356C0A483F11Q26777803-B8473330-0336-4CE8-B452-5512F1F15178Q26782506-2F164484-6F1A-4B8D-B098-821F8DE586A2Q26799499-404CECCD-0056-4444-A207-13BD7A555AB6Q26822434-AAF5990D-5375-49F6-AC88-AF4E6DC7CBB6Q26830385-5DEFB601-40E3-4861-9956-894822416137Q27016090-7EEC6294-E961-43E0-869B-A07EEC4104FEQ27853019-1DF646CE-5A59-4327-9C61-FD4783F70776Q27853039-523F8CD8-20D5-4BD6-8CBC-2191AC3C8264Q27853374-2C32B160-C1B4-4E7D-8E98-DDFDF5EB6774Q28071551-B6F564C2-959D-4BDA-91CA-6B26C1C86E19Q28071644-2285DDBD-9D49-4E65-AA0C-F6E1528F26ABQ28072539-97BF78B2-FA4F-49DD-91DA-753706A4490BQ28073658-5AE778D5-E067-457B-A193-28FFC2B98228Q28271752-6AED778C-FE0B-4B0C-B2FC-E4ABAB996926Q30276010-B74950D1-9383-4395-A694-E6595B7F2B4FQ30313870-470C79F5-C316-48E2-9A56-0EC68059A213Q30409637-168D242C-BACF-4A25-A501-3A5A696B62D9Q30561836-6E522E1F-CF09-44CE-98B5-568376DA3CB3Q30848149-DED54017-8A89-4FD8-B518-E59E34384745Q31056968-4B2A2260-9A9F-4A64-B8EE-303BFBE085F0Q31110460-6296DB5C-50FD-40CB-A374-A09B6F01AAA0Q31149503-6DEBEC47-8CE7-453A-9A1F-289A0C9F2106Q33163717-20702C29-0C57-44FA-B94F-A4AEC8729EF5Q33411708-E4096E99-578B-46E7-8FB3-AAA044949498Q33418257-E39796AD-A281-4311-8482-E11AA5E3A670Q33425190-03A8947D-5BEC-4A5B-B6B4-9EAFAF026111Q33429980-23294CD6-5C7C-4870-80DD-807A40665E32Q33600822-60D1647C-B802-4869-A64A-F04796E1C3EEQ33600826-CF5550F0-F1B9-4D2B-875F-223F295E17F7Q33701834-9A3B9243-D321-4ED5-8EE7-B96F76FC7E04Q33701840-1B8413B3-D2ED-450D-8862-EDD55A9BB911Q33701845-8C426095-0351-436A-A139-AA371BD60204Q33701852-51F6BC25-E27F-497B-922D-F544AC82B916
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Macmillan Publishers
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Blood Cancer Journal
@ast
Blood Cancer Journal
@da
Blood Cancer Journal
@de
Blood Cancer Journal
@en
Blood Cancer Journal
@es
Blood Cancer Journal
@fo
Blood Cancer Journal
@fr
Blood Cancer Journal
@is
Blood Cancer Journal
@it
Blood Cancer Journal
@kl
type
label
Blood Cancer Journal
@ast
Blood Cancer Journal
@da
Blood Cancer Journal
@de
Blood Cancer Journal
@en
Blood Cancer Journal
@es
Blood Cancer Journal
@fo
Blood Cancer Journal
@fr
Blood Cancer Journal
@is
Blood Cancer Journal
@it
Blood Cancer Journal
@kl
altLabel
BCJ
@en
prefLabel
Blood Cancer Journal
@ast
Blood Cancer Journal
@da
Blood Cancer Journal
@de
Blood Cancer Journal
@en
Blood Cancer Journal
@es
Blood Cancer Journal
@fo
Blood Cancer Journal
@fr
Blood Cancer Journal
@is
Blood Cancer Journal
@it
Blood Cancer Journal
@kl
P31
P3181
P1055
P1058
P1156
21100205926
P1277
P1476
Blood Cancer Journal
@en
P236
P3181
P407
P5115
P571
2011-01-01T00:00:00Z